| Barchart Demo Center |
$6.53
-0.16 (-2.39%)
as of Oct 18, 2019
as of Oct 18, 2019
| Last | 6.53 |
|---|---|
| Change | -0.16 (-2.39%) |
| Open | 6.61 |
| Prev. Close | 6.69 |
| Today's Range |
6.47
6.62
|
| 52wk Range |
4.90
15.89
|
| Volume | 33,900 |
| Avg Volume | 46,110 |
| Sector | SIC-2834 Pharmaceutical Preparations |
Perfomance Comparison
| Name | Today | 3-Month | 1-Year |
|---|---|---|---|
| EVLO |
 -2.39% |
 +11.24% |
-34.63% |
| DJIA |
 -0.95% |
 +1.49% |
+5.48% |
| S&P 500 |
-0.39% |
+1.64% |
+7.85% |
Key Statistics
| Annual EPS | -2.28 |
|---|---|
| Dividend Yield | 0.00% |
| P/E Ratio | N/A |
| Market Capitalization, $K | 214,480 |
| Weighted Alpha | -48.50 |
| Standard Deviation | -0.65 |
| Profit Margin | N/A |
| Beta | -0.17 |
Growth Rates
| YTD | -49.81% | |||
| 1-Year | -32.05% |
Opinion
| Sell | Hold | Buy |
Recent Headlines
Evelo Biosciences to Present at the 2019 Cantor Global
GlobeNewswire via COMTEX - Thu Sep 26, 04:05PM EDT
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that management will present a corporate overview at the 2019 Cantor Global (full story)
EVLO: 6.53 (-0.16)
Evelo Biosciences to Host Key Opinion Leader Symposium
GlobeNewswire via COMTEX - Fri Sep 20, 07:00AM EDT
Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that it will host a key opinion leader symposium on the unmet need in mild (full story)
EVLO: 6.53 (-0.16)
Evelo Biosciences Announces the Appointment of David
GlobeNewswire via COMTEX - Tue Sep 17, 07:01AM EDT
Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, announced today that David Epstein has been appointed chairman of its Board of Directors. M(full story)
EVLO: 6.53 (-0.16)
Evelo Biosciences to Present at the Morgan Stanley
GlobeNewswire via COMTEX - Wed Sep 04, 07:27PM EDT
Evelo Biosciences, Inc. (Nasdaq:EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that management will participate in a fireside ch(full story)
Evelo Biosciences Reports Positive EDP1815 Interim
GlobeNewswire via COMTEX - Tue Aug 06, 07:05AM EDT
-EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo-(full story)
EVLO: 6.53 (-0.16)